Primer on the Differential Diagnosis and Workup for Transthyretin Cardiac Amyloidosis

Kittleson, 2020, Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association, Circulation, 142, e7, 10.1161/CIR.0000000000000792 Dorbala, 2019, ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging, J Nucl Cardiol, 26, 2065, 10.1007/s12350-019-01760-6 Elsayed, 2020, Current updates on the management of AL amyloidosis, J Hematol, 10, 147, 10.14740/jh866 Sperry, 2017, Amyloid heart disease: genetics translated into disease-modifying therapy, Heart, 103, 812, 10.1136/heartjnl-2016-309914 Sperry, 2016, Recognizing transthyretin cardiac amyloidosis in patients with aortic stenosis: impact on prognosis, JACC Cardiovasc Imaging, 9, 904, 10.1016/j.jcmg.2015.10.023 Cyrille, 2014, Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis, Am J Cardiol, 114, 1089, 10.1016/j.amjcard.2014.07.026 Maurer, 2018, Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med, 379, 1007, 10.1056/NEJMoa1805689 Bruno, 2021, Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges, Heart Fail Rev, 26, 35, 10.1007/s10741-020-10010-8 Sperry, 2018, Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release, J Am Coll Cardiol, 72, 2040, 10.1016/j.jacc.2018.07.092 Donnelly, 2017, Cardiac amyloidosis: an update on diagnosis and treatment, Cleve Clin J Med, 84, 12, 10.3949/ccjm.84.s3.02 Sperry, 2016, Subtype-specific interactions and prognosis in cardiac amyloidosis, J Am Heart Assoc, 5, 10.1161/JAHA.115.002877 Phelan, 2017, Comparison of ventricular septal measurements in hypertrophic cardiomyopathy patients who underwent surgical myectomy using multimodality imaging and implications for diagnosis and management, Am J Cardiol, 119, 1656, 10.1016/j.amjcard.2017.02.009 Caballero, 2015, Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study, Eur Heart J Cardiovasc Imaging, 16, 1031 Castaño, 2017, Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, Eur Heart J, 38, 2879, 10.1093/eurheartj/ehx350 Senapati, 2016, Prognostic implication of relative regional strain ratio in cardiac amyloidosis, Heart, 102, 748, 10.1136/heartjnl-2015-308657 Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation, 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Sperry, 2020, Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT, J Nucl Cardiol, 27, 1802, 10.1007/s12350-020-02139-8 Masri, 2020, Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis, Circ Cardiovasc Imaging, 13, 10.1161/CIRCIMAGING.119.010249 Dorbala, 2020, How to image cardiac amyloidosis: a practical approach, JACC Cardiovasc Imaging, 13, 1368, 10.1016/j.jcmg.2019.07.015 Mishra, 2021, Cellular and molecular pathobiology of heart failure with preserved ejection fraction, Nat Rev Cardiol, 18, 400, 10.1038/s41569-020-00480-6 Nagueh, 2022, J Am Soc Echocardiogr, 35, 533, 10.1016/j.echo.2022.03.012